Mark Plante

Mark Plante
Mark K. Plante, MD, FRCS(C), FACS is the Chief of Urology and Urology Residency Program Director at the University of Vermont Medical Center. He is a Tenured Full Professor of Surgery and is the Urology Residency Program Director. He completed his medical degree and surgical training at McGill University in Montreal, Canada. Dr. Plante has been an invited speaker and visiting surgeon at conferences and universities throughout the United States, Canada, Eastern and Western Europe, Asia and Australia, most commonly for his expertise in new technologies in the treatment of Benign Prostatic Hyperplasia (BPH). This is also an area of focus for his numerous peer-reviewed presentations and publications. Specific to Prostatic Aquablation, Dr. Plante has served as an investigator in its early development as well participating in both the pivotal WATER I and II trials. He remains active in practice treating primarily patients with complicated BPH and urologic cancers.

Languages Spoken:

English, French

Medical School:

McGill

Residency:

McGill

Locations

University of Vermont Burlington, VT

111 Colchester Avenue, ACC level 5 - East Pavillion - UrologyBurlington, Vermont, 05446United States
802-847-2884 | Visit Website

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only